Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06892145 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE

StatusRecruiting
PhasePhase 1
Started2025-06-12
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 22, 2025 (before its estimated May 4, 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2025-12-18
Not Yet Recruiting→Recruiting Study Status, Oversight, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-04-02→confirmed 2025-06-12
Study sites1→2
2025-03-18
Original filing
This is a single-arm, open, dose-increasing and dose-expanding phase I clinical trial to investigate the safety, tolerability and cytodynamic characteristics of MC-1-50 cell preparation, and to preliminatively observe the efficacy of MC-1-50 cell preparation in patients with refractory SLE, and to explore the applicable dose regimen for phase II clinical trials.
Trial Details
NCT Number NCT06892145
Lead Sponsor Chongqing Precision Biotech Co., Ltd
Collaborators: Second Affiliated Hospital, Zhejiang University, School of Medicine
Conditions Systemic Lupus Erythematosus (SLE), Refractory
Enrollment 12 participants
Start Date 2025-06-12
Primary Completion 2026-05-04 (estimated)
Study Completion 2028-02-16 (estimated)
Updated on ClinicalTrials.gov 2025-12-22